Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote For All Three of the Company s Director Nominees Glass Lewis and ISS Recommend Shareholders Vote AGAIN

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS and Egan-Jones in Recommending MiMedx Shareholders Vote For All

Three of the Company s Director Nominees

Glass Lewis and ISS Recommend Shareholders Vote AGAINST the Two Shareholder Proposals

Submitted by Parker H. Pete Petit

MARIETTA, Ga., June 12, 2019 MiMedx Group, Inc. (OTC PINK: MDXG) ( MiMedx or the

Company ), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that leading independent proxy advisory firm Glass, Lewis & Co. ( Glass Lewis ) has joined

Institutional Shareholder Services ( ISS ) and Egan-Jones Proxy Services ( Egan-Jones ) in recommending MiMedx shareholders vote FOR the Company s three director nominees K. Todd Newton, Dr. Kathleen

Behrens Wilsey and Timothy R. Wright on the BLUE proxy card in connection with the Company s 2018 Annual Meeting of Shareholders to be held on June 17, 2019.

In its June 11, 2019 report, Glass Lewis concluded the following1:

In addition, Glass Lewis joined ISS in recommending shareholders vote against the two shareholder proposals submitted by Parker

H. Pete Petit on the BLUE card.

MiMedx urges shareholders to follow the recommendations of all three leading proxy advisory firms,

Glass Lewis, ISS and Egan-Jones, and vote FOR MiMedx s highly qualified nominees online or by telephone, using the BLUE proxy card TODAY.

Your Vote Is Important, No Matter How Many Or How Few Shares You Own.

If you have questions about how to vote your shares, or need additional assistance, please contact

the firm assisting MiMedx in the solicitation of proxies:

INNISFREE M&A INCORPORATED

Shareholders may call toll-free at 1 (877) 800-5195

Banks and Brokers may call collect at 1 (212) 750-5833

Sidley Austin LLP is acting as legal advisor to MiMedx.

MiMedx is an industry leader in advanced wound care and an emerging therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for

multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by

employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over 1.5 million allografts to date. For additional information, please visit www.mimedx.com.

Corporate & Investor Communications

Joele Frank, Wilkinson Brimmer Katcher

Andy Brimmer / Jed Repko

/ Annabelle Rinehart